UBS Group’s Ironwood Pharmaceuticals IRWD Stock Holding History

UBS Group’s Portfolio IRWD Stock Details IRWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$39.3M	Hold	11,200,320	–	–	0.01%	1881
2025 Q4	$37.7M	Hold	11,200,320	–	–	0.01%	1938
2025 Q3	$14.7M	Hold	11,200,320	–	–	﹤0.01%	2901
2025 Q2	$8.03M	Hold	11,200,320	–	–	﹤0.01%	3334
2025 Q1	$16.5M	Hold	11,200,320	–	–	﹤0.01%	2545
2024 Q4	$49.6M	Hold	11,200,320	–	–	0.01%	1472
2024 Q3	$46.1M	Hold	11,200,320	–	–	0.01%	1195
2024 Q2	$73M	Sell	11,200,320 -11,200,320	-50%	-$79.2M	0.02%	808
2024 Q1	$195M	Buy	+22,400,640	New	+$272M	0.05%	377
2022 Q1	–	Sell	-30,600	Closed	-$357K	–	10557
2021 Q4	$357K	Hold	30,600	–	–	﹤0.01%	5247
2021 Q3	$400K	Hold	30,600	–	–	﹤0.01%	4870
2021 Q2	$394K	Hold	30,600	–	–	﹤0.01%	4899
2021 Q1	$342K	Hold	30,600	–	–	﹤0.01%	5131
2020 Q4	$349K	Buy	+30,600	New	+$335K	﹤0.01%	4867
2015 Q2	–	Sell	-107,460	Closed	-$1.44M	–	8666
2015 Q1	$1.44M	Buy	+107,460	New	+$1.41M	﹤0.01%	3231

Other funds holding IRWD

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

UBS Group's IRWD Position: Q1 2026 in Review

UBS Group increased its Ironwood Pharmaceuticals (IRWD) stake by 83% in Q1 2026, buying an estimated $1.73M and bringing the position to 933,225 shares worth $3.28M. The position accounts for ﹤0.01% of the portfolio, ranked #4502.

UBS Group first reported a position in IRWD in Q4 2014 and has held it in 46 quarters since. The position peaked at $26.4M in Q1 2024. 226 funds tracked by Wall St. Rank hold IRWD as of Q1 2026.

UBS Group held 933,225 shares of Ironwood Pharmaceuticals worth $3.28M as of Q1 2026.
UBS Group bought 422,682 Ironwood Pharmaceuticals shares in Q1 2026, an estimated $1.73M.
Ironwood Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #4502 holding.
UBS Group first reported a position in Ironwood Pharmaceuticals in Q4 2014 and has held it in 46 quarters since.
UBS Group's Ironwood Pharmaceuticals position peaked at $26.4M in Q1 2024.
226 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.